J Korean Assoc Oral Maxillofac Surg.  1999 Jul;25(3):236-241.

ANTI-TUMOR EFFECT OF TAXOL AND CISPLATIN IN ORAL SQUAMOUS CELL CARCINOMA AND OSTEOSARCOMA CELL LINES

Affiliations
  • 1Department of Oral and Maxillofacial Surgery School of Dentistry, Seoul National University.

Abstract

OBJECT: Docetaxel(Taxol), which has been used for breast cancer and ovarian cancer and cisplatin were applied to KB and HOS cell lines. Relative cytotoxicity of each drug to cell lines and its efficiency was evaluated and analyzed for clinical application. METHOD AND METERIAL: Groups were defined by drugs and cell lines combination and were evaluated. We cultured cell line under routine environment and determined optimal cell number and drug concentration. Drugs were applied to cell lines and we measured the optical density with ELISA after MTT application. Statistical analysis was made and clinical availability was evaluated. IC50 and assay AUC could be calculated. Clinical availability was evaluated and comparisons of anti-tumor effect of each drug on cell lines were performed.
RESULTS
1. Anti-tumor effects of taxol and cisplatin on each cell lines showed time and dose dependent relations with significance statistically. 2. Assay AUC in IC50 was higher than clinically achievable AUC in all groups except cisplatin-KB group. Anti-tumor effect of taxol to KB cell line was higher than that of cisplatin in concentration calculated from the clinically achievable AUC. So, we could suggest that taxol could be also used as a antitumor durg for oral cancer. Further study that is, in vivo study, evaluation of combination therapy with other drug, and method of increasing of AUC would be necessary.

Keyword

Taxol; Chemosensitivity; Oral squamous cell carcinoma

MeSH Terms

Area Under Curve
Breast Neoplasms
Carcinoma, Squamous Cell*
Cell Count
Cell Line*
Cells, Cultured
Cisplatin*
Enzyme-Linked Immunosorbent Assay
Humans
Inhibitory Concentration 50
KB Cells
Mouth Neoplasms
Osteosarcoma*
Ovarian Neoplasms
Paclitaxel*
Cisplatin
Paclitaxel
Full Text Links
  • JKAOMS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr